Skip to content

News Category: Health & Medical

Non-invasive in vitro diagnostic (IVD) test enables early detection of colorectal cancer

By asianet

The DNA Methylation Detection Kit for Human SDC2, ADHFE1 and PPP2R5C Genes (Real-Time PCR), the colorectal cancer early detection product under BGI’s wholly-owned subsidiary BGI Biotechnology (Wuhan) Co., Ltd., has recently obtained the medical device market access certification from Agencia Nacional de Vigilancia Sanitaria (hereinafter referred to as ANVISA), with a registration number 80117581027. Stool … Continued

PeproMene Bio, Inc. Announced Complete Response of The First Patient Treated in Its B-cell Non-Hodgkin Lymphoma (B-NHL) Phase 1 Clinical Trial of PMB-CT01 (BAFFR-CAR T Cells) at City of Hope

By asianet

PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the first patient treated in its phase 1 relapsed or refractory B-cell Non-Hodgkin Lymphoma (r/r B-NHL) clinical trial of PMB-CT01 (BAFFR-CAR T Cells) has reached Complete Response at 1-month post treatment. The trial is taking place … Continued

Huaiyin in Jinan, Shandong, Intent on Transforming into China’s Top Health and Wellness City

By asianet

According to information released on December 13 by the People’s Government of Huaiyin District, Huaiyin will expend all necessary effort on building a new medical science city comprising an international smart medical city, a green health demonstration zone and a health and wellness tourism demonstration site. This will be achieved by fully capitalizing on the … Continued

Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination

By asianet

Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, and the Menarini Group (“Menarini”), a privately-held, leading international pharmaceutical company, today announced a clinical trial collaboration and supply agreement. This agreement covers the execution of a Phase 2 clinical trial to evaluate the novel combination of Carrick’s samuraciclib (CT7001), an oral and … Continued

Health and Hydrogen launches one of the first medical-grade Molecular Hydrogen Inhalation Machine HAH-301

By asianet

Molecular Hydrogen Inhalation therapy is now extensively used for its many health benefits, such as reducing inflammation, improving cellular function, and protecting against oxidative stress. Health And Hydrogen [ https://healthandhydrogen.com/ ] recently launched a revolutionary, easy-to-use medical-grade molecular hydrogen inhalation HAH- 301 [ https://healthandhydrogen.com/product/ ] device to provide patients with these benefits. This device can … Continued

CES 2023:OMRON Healthcare Introducing Initiatives to Advance Its Vision of “Going for Zero” — Elimination of Heart Attack and Stroke

By asianet

OMRON Healthcare Co., Ltd. (hereinafter the Company) will exhibit at CES 2023 (*), the world’s largest consumer tech show taking place in Las Vegas from Thursday, January 5, through Sunday, January 8. At the show, the Company will showcase the innovative medical devices and digital services that have been introduced over the last 50 years … Continued

Novavax Announces Pricing of $65 Million Public Offering of Common Stock

By asianet

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an underwritten public offering to sell 6,500,000 shares of its common stock at a public offering price of $10.00 per share, or $65 million worth of shares of its common stock. In … Continued

Novavax Announces Pricing of $150 Million Offering of Convertible Senior Notes

By asianet

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an offering of $150 million aggregate principal amount of its 5.00% convertible senior notes due 2027 (the “notes”). The notes are being offered and sold only to persons reasonably believed to be … Continued

Novavax Announces Proposed Offering of $125 Million of Convertible Senior Notes

By asianet

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed offering of $125 million aggregate principal amount of convertible senior notes due 2027 (the “notes”). The notes will be offered and sold only to persons reasonably believed to be qualified institutional buyers pursuant … Continued

Pharming announces positive interim analysis data from open-label extension study of leniolisib in presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

By asianet

V. Koneti Rao, MD, shared new evidence of long-term safety and hematologic response in patients who received leniolisib to treat APDS, a rare primary immunodeficiency Interim analysis demonstrated leniolisib to be well tolerated and indicated the durability of the efficacy results seen in the Phase II/III randomized, controlled trial Pharming Group N.V. (“Pharming” or “the … Continued